Sensitivity to 5,10-dideazatetrahydrofolate is fully conserved in a murine leukemia cell line highly resistant to methotrexate due to impaired transport mediated by the reduced folate carrier

Clinical Cancer Research

Volumn 6, Issue 8, 2000, Pages 3304-3311

  Zhao, Rongbao ^a   Gao, Feng ^a   Babani, Solomon ^a   David Goldman, I ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CARRIER PROTEIN; COMPLEMENTARY DNA; FOLIC ACID; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; LOMETREXOL; METHIONINE; METHOTREXATE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; RNA; VALINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; DRUG RESISTANCE; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINO ACIDS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; DNA, COMPLEMENTARY; DRUG RESISTANCE, NEOPLASM; FOLIC ACID ANTAGONISTS; LEUCOVORIN; LEUKEMIA L1210; MEMBRANE PROTEINS; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MICE; TETRAHYDROFOLATES; TRANSFECTION;

EID: 0033883618     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Fahre, I., Fabre, G., and Goldman, I. D. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res., 44: 3190-3195, 1984.
2. Matherly, L. H., Seither, R. L., and Goldman, I. D. Metabolism of the diaminoantifolates: biosynthesis and pharmacology of the 7-hydroxyl and polyglutamyl metabolites of methotrexate and related antifolates. Pharmacol. Ther., 35: 27-56, 1987.
3. Shane, B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam. Horm., 45: 263-335, 1989.
4. Moran, R. G., Baldwin, S. W., Taylor, E. C., and Shih, C. The 6S-and 6R-diastereomers of 5,10-dideaza-5,6,7,8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis. J. Biol. Chem., 264: 21047-21051, 1989.
5. Baldwin, S. W., Tse, A., Gossett, L. S., Taylor, E. C., Rosowsky, A., Shih, C., and Moran, R. G. Structural features of 5,10-dideaza-5,6,7,8-tetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry, 30: 1997-2006, 1991.
6. Sanghani, S. P., and Moran, R. G. Tight binding of folate substrates and inhibitors to recombinant mouse glycinamide ribonucleotide formyltransferase. Biochemistry, 36: 10506-10516, 1997.
7. Mendelsohn, L. G., Shih, C., Schultz, R. M., and Worzalla, J. F. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Investig. New Drugs, 14: 287-294, 1996.
8. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., Judson, I. R., and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
9. Taylor, E. C., Kuhnt, D., Shih, C., Rinzel, S. M., Grindey, G. B., Barredo, J., Jannatipour, M., and Moran, R. G. A dideazatetrahydrofolate analogue lacking a chiral center at C-6,N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl] benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J. Med. Chem., 35: 4450-4454, 1992.
10. Shih, C., Chen, V. J., Gossett, L. S., Gates, S. B., MacKellar, W. C., Habeck, L. L., Shackelford, K. A., Mendelsohn, L. G., Soose, D. J., Patel, V. F., Andis, S. L., Bewley, J. R., Rayl, E. A., Moroson, B. A., Beardsley, G. P., Kohler, W., Ratnam, M., and Schultz, R. M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res., 57: 1116-1123, 1997.
11. Schultz, R. M., Patel, V. F., Worzalla, J. F., and Shih, C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res., 19: 437-443, 1999.
12. Kaye, S. B. New antimetabolites in cancer chemotherapy and their clinical impact. Br. J. Cancer, 78 (Suppl. 3): 1-7, 1998.
13. Takimoto, C. H. Antifolates in clinical development. Semin. Oncol., 24: S18-S18, 1997.
14. Cunningham, D., Zalcberg, J. R., Rath, U., Olver, I., Van Cutsem, E., Svensson, C., Seitz, J. F., Harper, P., Kerr, D., Perez-Manga, G., Azab, M., Seymour, L., Lowery, K., Ackland, S. P., Basser, R. L., Clarke, S. J., Goldstein, D., Green, M. D., Grygiel, J. J., McKendrick, J. J., Millward, M. J., Olver, I. N., Tattersall, M. H. N., and Thomson, D. B. Tomudex' (ZD1694). Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur. J. Cancer, 31A: 1945-1954, 1995.
15. Rinaldi, D. A. Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Semin. Oncol., 26 (Suppl. 6): 82-88, 1999.
16. O'Dwyer, P. J. Overview of phase II trials of MTA in solid tumors. Semin. Oncol., 26 (Suppl. 6): 99-104, 1999.
17. Westerhof, G. R., Schornagel, J. H., Kathmann, I., Jackman, A. L., Rosowsky, A., Forsch, R. A., Hynes, J. B., Boyle, F. T., Peters, G. J., Pinedo, H. M., and Jansen, G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular- structure and biological activity. Mol. Pharmacol., 48: 459-471, 1995.
18. Jackman, A. L., Kelland, L. R., Kimbell, R., Brown, M., Gibson, W., Aherne, G. W., Hardcastle, A., and Boyle, F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br. J. Cancer, 71: 914-924, 1995.
19. Kobayashi, H., Takemura, Y., and Ohnuma, T. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates. Cancer Lett., 124: 135-142, 1998.
20. Dixon, K. H., Lanpher, B. C., Chiu, J., Kelley, K., and Cowan, K. H. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J. Biol. Chem., 269: 17-20, 1994.
21. Williams, F. M. R., Murray, R. C., Underhill, T. M., and Flintoff, W. F. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. J. Biol. Chem., 269: 5810-5816, 1994.
22. Williams, F. M. R., and Flintoff, W. F. Isolation of a human cDNA that complements a mutant hamster cell defective in methotrexate uptake. J. Biol. Chem., 270: 2987-2992, 1995.
23. Prasad, P. D., Ramamoorthy, S., Leibach, F. H., and Ganapathy, V. Molecular cloning of the human placental folate transporter. Biochem. Biophys. Res. Commun., 206: 681-687, 1995.
24. Moscow, J. A., Gong, M. K., He, R., Sgagias, M. K., Dixon, K. H., Anzick, S. L., Meltzer, P. S., and Cowan, K. H. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res., 55: 3790-3794, 1995.
25. Wong, S. C., Proefke, S. A., Bhushan, A., and Matherly, L. H. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J. Biol. Chem., 270: 17468-17475, 1995.
26. Zhao, R., Sharina, I. G., and Goldman, I. D. Pattern of mutations that results in loss of reduced folate carrier function under antifolate selective pressure augmented by chemical mutagenesis. Mol. Pharmacol., 56: 68-76, 1999.
27. Zhao, R., Assaraf, Y. G., and Goldman, I. D. A reduced carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J. Biol. Chem., 373: 7873-7879, 1998.
28. Schuetz, J. D., Matherly, L. H., Westin, E. H., and Goldman, I. D. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line. J. Biol. Chem., 263: 9840-9847, 1988.
29. Brigle, K. E., Spinella, M. J., Sierra, E. E., and Goldman, I. D. Characterization of a mutation in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J. Biol. Chem., 270: 22974-22979, 1995.
30. Zhao, R., Seither, R., Brigle, K. E., Sharina, I. G., Wang, P. J., and Goldman, I. D. Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells. J. Biol. Chem., 272: 21207-21212, 1997.
31. Matherly, L. H., and Angeles, S. M. Determinants of the disparate antitumor effects of (6R)5, 10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward methotrexate resistant CCRF-CEM cells, characterized by severely impaired antifolate membrane transport. Adv. Exp. Med. Biol., 338: 783-786, 1993.
32. Zhao, R., Assaraf, Y. G., and Goldman, I. D. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J. Biol. Chem., 273: 19065-19071, 1998.
33. Yang, C-H., Dembo, M., and Sirotnak, F. M. Relationships between carrier-mediated transport of folate compounds by L1210 leukemia cells: evidence for multiplicity of entry routes with different kinetic properties expressed in plasma membrane vesicles. J. Membr. Biol., 75: 11-20, 1983.
34. Assaraf, Y. G., Babani, S., and Goldman, I. D. Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in Chinese hamster ovary cells. J. Biol. Chem., 273: 8106-8111, 1998.
35. Zhao, R., Gao, F., and Goldman, I. D. Discrimination among reduced folates and methotrexate as transport substrates by a phenylalanine substitution for serine within the predicted eighth transmembrane domain of the reduced folate carrier. Biochem. Pharmacol., 58: 1615-1624, 1999.
36. Goldman, I. D. Transport energetics of the folic acid analogue, methotrexate, in L1210 cells: enhanced accumulation by metabolic inhibitors. J. Biol. Chem., 244: 3779-3785, 1969.
37. Schlemmer, S. R., and Sirotnak, F. M. Energy-dependent efflux of methotrexate in L1210 leukemia cells. Evidence for the role of an ATPase obtained with inside-out plasma membrane vesicles. J. Biol. Chem., 267: 14746-14752, 1992.
38. Saxena, M., and Henderson, G. B. Identification of efflux systems for large anions and anionic conjugates as the mediators of methotrexate efflux in L1210 cells. Biochem. Pharmacol., 51: 975-982, 1996.
39. Tse, A., and Moran, R. G. Cellular folates prevent polyglutamation of 5,10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites. J. Biol. Chem., 273: 25944-25952, 1998.
40. Jansen, G., Mauritz, R., Drori, S., Sprecher, H., Kathmann, I., Bunni, M., Priest, D. G., Noordhuis, P., Schornagel, J. H., Pinedo, H. M., Peters. G. J., and Assaraf, Y. G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem., 273: 30189-30198, 1998.
41. Alati, T., Worzalla, J. F., Shih, C., Bewley, J. R., Lewis, S., Moran, R. G., and Grindey, G. B. Augmentation of the therapeutic activity of lometrexol-(6-R)5,10-dideazatetrahydrofolate. Cancer Res., 56: 2331-2335, 1996.
42. Jacques, P. F., Selhub, J., Bostom, A. G., Wilson, P. W., and Rosenberg, I. H. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N. Engl. J. Med., 340: 1449-1454, 1999.
43. Gorlick, R., Goker, E., Trippelt, T., Steinherz, P., Elisseyeff, Y., Mazumdar, M., Flintoff, W. F., and Bertino, J. R. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood, 89: 1013-1018, 1997.
44. Matherly, L. H., Taub, J. W., Ravindranath, Y., Proefke, S. A., Wong, S. C., Gimotty, P., Buck, S., Wright, J. E., and Rosowsky, A. Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood, 85: 500-509, 1995.